Please ensure Javascript is enabled for purposes of website accessibility

bluebird bio Beats Its Q4 Revenue Target but Misses on EPS

By Mark Prvulovic – Updated Feb 18, 2020 at 9:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This gene-therapy developer delivered decent revenue figures, but its losses continue to grow.

bluebird bio (BLUE 11.05%) announced its fourth-quarter and full-year financial results on Tuesday afternoon. The clinical-stage biotech's stock price fell a bit in after-hours trading as investors reacted to the mixed report.

Although the company beat its revenue target, bluebird failed to hit Wall Street analysts' consensus estimate on earnings per share. The company reported total revenue of $10.0 million, the majority of which came from collaboration agreements. Although that was down substantially from the $19.2 million it reported in the prior-year period, it was still better than the $9.2 million expected by Wall Street analysts.

Abstract picture of two strands of DNA.

Image source: Getty Images

bluebird reported a pretty significant net loss for the quarter -- $223.3 million. That was almost 50% higher than Q4 2018's $149.0 million net loss. In terms of earnings per share, bluebird's net loss was $4.04, which was worse than the net loss of $3.79 that analysts were expecting.

Further details

While the biotech is still losing a significant amount of money, it has $1.24 billion in cash and cash equivalents on its balance sheet, enough to last it a little over a year at its current rate of expenditure.

bluebird currently has 21 drug candidates at the moment, several in late-stage clinical trials. Among the most promising is Zynteglo (also known as LentiGlobin), a treatment for transfusion-dependent beta-thalassemia (TDT). The treatment received approval in Germany as a treatment for TDT patients; bluebird expects to submit Zynteglo for approval by the U.S. Food and Drug Administration later this year.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bluebird Bio. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$6.33 (11.05%) $0.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.